Lupin Launches Generic Cancer Drug in US - Doxorubicin Hydrochloride Liposome Injection
Aug 29, 2024 16:11
Lupin has launched a generic version of Doxorubicin Hydrochloride Liposome Injection (Doxil) in the US market, treating ovarian cancer, AIDS-related Kaposi's Sarcoma, and multiple myeloma.
New Delhi, Aug 29 (PTI) Drug firm Lupin on Thursday said it has launched a generic cancer treatment drug in the US market.
The company said it has launched Doxorubicin Hydrochloride Liposome Injection single-dose vials in the US.
The Mumbai-based drug maker introduced the product after its alliance partner, ForDoz Pharma Corporation, USA (ForDoz) received approval from the USFDA, Lupin said in a statement.
The company's product is a generic version of Baxter Healthcare Corporation's Doxil which is indicated for the treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi's Sarcoma, and multiple myeloma.
As per the Iqvia MATdata, Doxorubicin Hydrochloride Liposome Injection had an estimated annual sales of USD 40.9 million in the US.
Lupin shares on Thursday ended 0.21 per cent at Rs 2,195.20 apiece on the BSE.
Rediff.com »
Market News » Lupin Launches Generic Cancer Drug in US - Doxorubicin Hydrochloride Liposome Injection
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.